FOXO4-DRI

Experimental Peptide

FOXO4-DRI is an experimental D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. Reported senolytic effects are preclinical; human dosing, safety, pharmacokinetics, and clinical benefit have not been established.

Pharmacokinetic model

A route-level PK model for foxo4-dri is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Experimental Peptide
Suggested cadence: once daily

Research behind this entry

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Baar MP, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ · Cell, 2017 DOI
The investigators designed a FOXO4-targeting peptide and reported selective effects in senescent cells plus functional changes in accelerated- aging and naturally aged mice. It is a cell-and-mouse study, not evidence of…

1 published study referenced in the app, each with a plain-language summary.